Psilocybin assisted therapy for eating disorders is still early, with one small feasibility study in anorexia nervosa and a growing set of registered trials, while reviews through 2025 describe the evidence as limited and the safety questions as especially important for this population.
What psilocybin assisted therapy means in studies
In studies, psilocybin assisted therapy usually means psilocybin is given in a controlled clinical setting with structured psychological support before, during and after dosing. You are not taking a substance at home and checking in later. The core elements are planned in advance and delivered by a trained team using a defined protocol.
Most protocols include these components.
- Screening for medical risk, psychiatric history and current stability
- Preparation sessions that set expectations, build rapport and review coping skills
- One or more supervised dosing sessions with monitoring
- Integration sessions and follow-up visits that track symptoms and adverse events
For eating disorders, researchers pay close attention to factors that can change risk on dosing day, like cardiovascular status, electrolyte risk, current nutritional stability and patterns of compulsive behavior. That attention shows up in eligibility criteria and in the monitoring plan.
It also helps to know what psilocybin assisted therapy does not mean in studies. It does not mean that psilocybin replaces medical monitoring, nutrition support or ongoing therapy that addresses eating disorder behaviors. In protocols, those supports are part of the safety frame and often part of the overall care picture that the study team reviews with you.
Finally, the word assisted is practical. It reflects that the session is not treated like a simple medication visit. Your mindset going in, the physical environment and the support you receive during difficult moments are treated as meaningful parts of the intervention. Reviews focused on eating disorders highlight this because symptom patterns often involve control, rigidity, anxiety and shame, which can surface strongly during an altered state. (ScienceDirect)
What reviews and early trials report so far
As of 2025, the strongest direct clinical signal comes from a small open-label feasibility study of psilocybin therapy in adult females with anorexia nervosa. This kind of study is designed to answer basic questions first. Can people complete the protocol. What adverse events occur. Do symptom measures move in a direction that justifies larger trials.
In that feasibility study, the sample size was very small. That limits what you can conclude about efficacy. Still, feasibility data can be valuable for eating disorders because dropout risk can be high and safety planning can be complex. In the published report, investigators described acceptability and safety monitoring and tracked changes in eating disorder and related psychological measures over follow-up.
Reviews that compile early clinical work and registered trials make a similar point. The evidence base is thin, most data come from small designs and the field is still working out best practices for endpoints, follow-up windows and participant selection. A 2025 systematic review that searched the literature and trial registries through mid 2024 describes a limited set of original research studies and a larger set of registered trials, with anorexia nervosa as the main focus and much less direct data for bulimia nervosa and binge eating disorder.
When you read these reviews, you will often see a few themes repeated.
One theme is mechanistic plausibility paired with limited clinical proof. Authors discuss how psilocybin affects serotonin signaling and how changes in cognitive flexibility, threat learning and rigid self-referential thinking might be relevant to eating disorder symptoms. Then they return to the same reality check. Clinical evidence in eating disorders is still preliminary and needs larger controlled trials.
Another theme is heterogeneity. Eating disorders are not one uniform condition. Anorexia nervosa, bulimia nervosa and binge eating disorder involve different medical risks, different behavior patterns and different comorbidities. Even within one diagnosis, people differ by duration of illness, trauma history, autistic traits, obsessive compulsive traits and substance use. Reviews emphasize that trial design has to take this into account because it affects both safety and interpretation of outcomes.
A third theme is the gap between general psychedelic findings and eating disorder specific findings. Psilocybin has more data in other psychiatric conditions, but you cannot automatically map those results onto eating disorders. The medical risk profile is different, the behavioral reinforcement loops are different and the risk of symptom substitution can be different. Reviews focused on eating disorders point out that this is one reason the field needs eating disorder specific trials rather than broad inference.
You will also see a growing number of registered anorexia nervosa trials that differ in age range, dose approach and the number of dosing sessions. Some focus on adults, others focus on young adults. Some use one high dose session, others include two dosing sessions with preparation and integration. Registry entries show that investigators are actively testing what a workable protocol looks like for this population.
If you are searching for where the evidence stands today, it is fair to say this.
- Direct clinical evidence in eating disorders is still small and early
- Anorexia nervosa has the most direct psilocybin trial attention so far
- The field is using feasibility work and early phase trials to build safer, more interpretable next studies
Safety considerations that matter more in eating disorders
Safety planning is central for any psilocybin study, yet eating disorders add specific concerns that can change risk even when a protocol looks similar on paper.
One concern is cardiovascular risk. Eating disorders, especially anorexia nervosa, can be associated with bradycardia, orthostatic changes, QT prolongation risk and arrhythmia risk that can be worsened by electrolyte shifts. Psilocybin can raise heart rate and blood pressure during the acute period, so protocols need careful screening and monitoring. Narrative reviews focused on anorexia nervosa highlight the importance of medical screening and vital sign monitoring in this population. (Springer)
Another concern is electrolyte stability and hydration. Purging, laxative use and severe restriction can affect potassium, sodium and magnesium, which can raise cardiac risk. In practical terms, this can affect eligibility, the timing of labs and the threshold for delaying dosing if clinical values raise concern. Reviews and trial descriptions emphasize safety planning around these medical variables. (Springer)
Medication interactions also come up more often than people expect. Many people with eating disorders take antidepressants, anxiolytics or medications tied to sleep and gastrointestinal symptoms. Protocols differ on what they allow. Some require washouts for certain medications. Medication changes can carry their own risk for relapse, withdrawal symptoms and destabilization. That means safety is not only about dosing day. It includes the weeks leading up to dosing and the period after. (PMC)
Another safety topic is suicidality and self-harm risk, which can be elevated in eating disorders. Trials typically screen for current instability and have procedures for crisis response. Psilocybin sessions can surface intense emotion, grief, shame or trauma content. A protocol needs clear steps for what happens if you feel unsafe during or after the session. Reviews call for careful participant selection and follow-up plans in eating disorders for this reason. (ScienceDirect)
You also have behavioral risks that are specific to eating disorders.
Rigid control themes can show up during dosing as fear of bodily sensations, fear of loss of control or a drive to manage the experience through restriction or avoidance. A protocol can address this by preparation work that teaches you what to do when control urges spike, and by monitoring that accounts for food intake and hydration needs on dosing day. (ScienceDirect)
Compensatory behaviors can also complicate follow-up. If you feel emotionally activated after a session, you might be more likely to return to restriction, purging or exercise compulsion. That is one reason eating disorder focused reviews stress integration, close follow-up and alignment with a care team that can track behavioral changes after the session. (ScienceDirect)
Finally, there is a safety consideration tied to interpretation. If a study reports improved mood but does not measure eating disorder behaviors in a detailed way, it can miss symptom shifts that are clinically significant. For example, you might feel less depressed while restriction increases. That is not an outcome a trial should miss. Reviews point to trial design choices that need to capture both medical and behavioral realities, not just general mood. (PMC)
What future trials still need to answer
Eating disorder trials with psilocybin have clear open questions, and many are visible when you compare early feasibility work to the registered trial pipeline.
One question is who the right participant population is for early phase trials. Some studies recruit adults, some recruit young adults, and protocols vary in illness duration and prior treatment resistance. These differences change safety, dropout risk and how you interpret outcomes. Trial listings show this variability in inclusion criteria and study design. (clinicaltrials.gov)
Another question is dose strategy. Some protocols use a single high-dose session, others use two dosing sessions with a planned step up. A registry entry for a young adult study describes two dosing sessions with preparation and integration in between, which is a practical approach for testing tolerability and response over time. (UCSF Clinical Trials)
A third question is the role of family involvement and support. Some registered designs include family participation as part of the study flow. That is important because eating disorder outcomes often depend on the environment you return to, and on how support people respond to relapse signs. Registry descriptions show that trial teams are testing how to integrate this into protocols. (UCSF Clinical Trials)
Outcome selection remains a major gap. Future trials need clear primary endpoints that match the clinical reality of eating disorders. That often means multi-domain measurement.
- Eating disorder symptom scales tied to restriction, bingeing and purging
- Behavioral measures like frequency and intensity of key behaviors
- Medical measures tied to safety and stability
- Comorbid measures for anxiety, depression and obsessive compulsive traits
- Follow-up length that can capture relapse patterns and delayed adverse events (PMC)
Blinding and control conditions are also hard. Psychedelic trials often struggle with blinding because subjective effects can be obvious. Eating disorder populations add extra sensitivity because expectancy and treatment narratives can strongly shape behavior change. Future trials need thoughtful methods to manage expectancy effects, and reviews often flag this as a methodological challenge in the broader psychedelic field that applies strongly here. (ScienceDirect)
Another open question is how to integrate psilocybin sessions with ongoing evidence-based eating disorder care. If your outpatient team is doing nutrition rehabilitation and therapy, the protocol needs a plan for coordination, medication management and relapse monitoring. The research goal is to test a defined intervention, but participant safety requires connection to ongoing care. Eating disorder focused reviews point to this need for coordination and careful follow-up. (PMC)
Finally, long-term safety data are missing. A feasibility study can show that a protocol is workable and that acute safety signals were manageable in a small sample. It cannot show how outcomes hold up across large diverse populations or how rare adverse events show up. That is why larger trials and longer follow-ups are still needed before you can treat early findings as settled. (Nature)
How to read headlines without overreaching
Headlines tend to compress nuance. Eating disorder stories can be especially vulnerable to this because people are searching for hope and because current treatments can feel slow and hard.
A useful first step is to classify what kind of evidence the headline is pointing to. You can often tell from a few cues.
If the headline is based on a feasibility study, it is mainly telling you the protocol could be delivered and monitored in a small group. It may also show symptom movement, but it is not built to prove efficacy. The anorexia nervosa feasibility study is a good example of why this distinction matters, since the sample was small and open-label. (Nature)
If the headline is based on a narrative review, it is a synthesis of concepts, early data and hypotheses, and it may highlight gaps and mechanisms more than it provides clinical proof. A 2024 narrative review focused on anorexia nervosa discusses early work and theoretical framing, which can help you understand why the field is interested, yet it does not substitute for controlled trials. (Springer)
If the headline is based on a systematic review, it usually means the authors used a defined method to gather studies and registered trials, then evaluated what exists and what is missing. The 2025 systematic review focused on eating disorders and psilocybin is useful because it documents both published work and registered trials, which helps you separate active research from hype. (PMC)
Another step is to look for what the article actually measured. Improved mood is not the same as reduced restriction. Reduced anxiety is not the same as normalized eating patterns. If the outcome measures do not match eating disorder behaviors and medical stability, you should treat the headline as incomplete.
You should also watch for hidden selection effects. Early studies often exclude people at higher medical risk, people with active substance use and people with unstable psychiatric symptoms. That can be the right call for early safety, but it means the findings may not apply to many real-world patients. Trial listings often show these exclusion patterns in plain text. (clinicaltrials.gov)
Another headline trap is treating registered trials as proven results. A trial being registered means it is planned or underway. It does not mean it has positive outcomes. Registry entries are still useful because they show what questions researchers are taking seriously, like age range, number of dosing sessions and safety endpoints. (clinicaltrials.gov)
Finally, be careful about broad claims like cure or breakthrough. Eating disorders are chronic for many people, relapse is common and behavior change often needs sustained support. Early psychedelic work can be promising without being definitive. Reviews in this space repeatedly frame the evidence as preliminary and call for more rigorous trials. (ScienceDirect)
Questions to take to a care team
If you are considering applying to a trial or you are trying to interpret research for your own care decisions, talk with your care team first. You can bring specific questions that map to the real risks and unknowns in this area.
Here are practical questions that often help.
- Based on my diagnosis and current stability, what risks stand out for me
- Do I have medical risks that could be worsened by acute increases in heart rate or blood pressure
- Do I have electrolyte risks from restriction, purging or laxative use that need monitoring
- How would medication changes affect relapse risk or mood stability if a protocol required a washout
- If I did a study, how would we coordinate nutrition support and therapy around dosing and follow-up
- What relapse warning signs should we watch for in the weeks after a session
- What would a safety plan look like if I had insomnia, anxiety spikes or suicidal thoughts after dosing
- How would we track eating disorder behaviors in a concrete way so mood improvement does not hide symptom worsening
You can also ask your team to help you read a study description with a clinical lens. Ask what the inclusion criteria imply about risk and generalizability. Ask what the outcomes measure and what they do not measure. Ask what the follow-up window is, since short follow-up can miss relapse patterns.
If you decide to look for trials, ask your care team to help you plan the logistics too. Dosing days are usually long. Follow-up visits can be frequent early on. You may need a support person for transport after dosing. Those practical realities affect stress load, and stress load affects eating disorder symptoms.
Near the end of your planning, it can help to understand how a Massachusetts-based psychedelic research group approaches psilocybin science and therapeutic integration. We are Rose Hill Life Sciences, a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and we are based in Massachusetts.
